APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.
12 July 2011
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners
13 June 2011
APR Applied Pharma Research s.a. and Labtec GmbH announce Ondansetron Oral Dispersible Film (“ODF”) is now available for licensing in Europe and selected non European countries, after having received marketing authorization in most countries of Europe.
Donepezil ODF will be developed as an Orodispersible film available in the two more dosages of Aricept (5 and 10mg).
Donepezil ODF offers competitive advantages versus Aricept tablets and Aricept ODT (Aricept Evess):
> higher compliance vs Aricept Tablets: swallowing is easier and water is not needed, once the film is put in the mouth
there is no possibility to extract the medicine from the mouth.
> higher compliance vs Aricept Evess : easier to be handled, stored and taken away;
